Physician

Richard C Cherny, M.D.

According to 2025 Medicare claims, Richard Cherny, M.D. (NPI: 1659351484) practices hematology/oncology in the Syracuse, NY market, with the plurality of this provider's patient population coming from Onondaga, NY. This provider's primary affiliated billing organization is HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, PC (NPI: 1902885429; TIN: 161184100) and primary practice location at 13057-9248. Cherny is affiliated with the Bassett Accountable Care Partners, LLC (ACO ID: A2612), participating under the MSSP model.

Cherny's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,241 traditional Medicare patients, billed 616,572 HCPCS/CPT codes, and received $10,775,751 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 370 prescription claims across 145 beneficiaries totaling $164,092 in drug costs, led by Eliquis (Apixaban). DME data shows 163 claims. Open Payments data shows 1 records totaling $18. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $365,241 to $10,775,751. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $414,808 and ending at $164,092. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	778	25,329	$365,241
2016	769	23,172	$317,641
2017	699	29,320	$363,515
2018	1,016	124,527	$1,774,074
2019	1,093	168,402	$2,377,312
2020	1,269	415,188	$6,502,476
2021	1,357	487,199	$8,161,201
2022	1,304	526,451	$7,932,223
2023	1,287	567,326	$9,088,364
2024	1,241	616,572	$10,775,751

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	120	359	$414,808
2016	97	280	$234,291
2017	90	288	$228,229
2018	127	409	$201,403
2019	143	473	$385,886
2020	128	482	$135,089
2021	131	414	$518,712
2022	113	365	$274,777
2023	118	361	$186,327
2024	145	370	$164,092

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	30	153	$53,119
2016	13	69	$1,800
2017	N/R	35	$1,296
2018	26	157	$16,418
2019	16	140	$5,897
2020	31	198	$1,895
2021	53	268	$587
2022	67	365	$2,513
2023	36	238	$1,000
2024	13	163	$1,098

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	324	1,237	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	357	459	$65
96372	Injection of drug or substance under skin or into muscle	298	975	$11
36415	Insertion of needle into vein for collection of blood sample	332	1,201	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	324	1,061	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	30	1,150	$21,745
Xarelto	Rivaroxaban	23	930	$17,499
Hydroxyurea	Hydroxyurea	24	1,345	$520
Anastrozole	Anastrozole	46	2,340	$456
Tamoxifen Citrate	Tamoxifen Citrate	27	1,530	$407

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	21	$557
Q0166	Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen	N	N/R	97	$279
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	21	$251
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	N	13	24	$12

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$18	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard C. Cherny, M.D.?

Tedicare shows public-source Medicare data for Richard C. Cherny, M.D. (NPI 1659351484), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard C. Cherny, M.D. have ACO affiliation data?

Richard C. Cherny, M.D. is shown with ACO affiliation data for Bassett Accountable Care Partners, LLC (MSSP, ACO ID A2612).

What billing organization is linked to Richard C. Cherny, M.D.?

Richard C. Cherny, M.D. is linked to HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, PC (billing NPI 1902885429) in the available physician profile data.

Does Richard C. Cherny, M.D. have Open Payments data?

Richard C. Cherny, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.